Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Effectiveness Observational Study of Anti IL-6 Tocilizumab in Hospital Admitted Patients With Severe COVID-19 Pneumonia.

NCT04924829 is registered in ClinicalTrials.gov with Hospital Italiano de Buenos Aires as lead sponsor.

NCT NCT04924829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04924829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Effectiveness Observational Study of Anti IL-6 Tocilizumab in Hospital Admitted Patients With Severe COVID-19 Pneumonia.
Lead sponsor
Hospital Italiano de Buenos Aires
Phase
Observational
Overall status
Unknown status
Start date
June 1, 2021
Completion date
August 1, 2021
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe covid 19 pneumonia, tocilizumab